Physician profile
Robert A Cook
NPI 1568407690
$10,032.57
in general payments reported to CMS, 2019-2025
61 companies · $1,283 in 2025
The $1,283 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,080 · 2020: $1,201 · 2021: $2,127 · 2022: $1,619 · 2023: $1,511 · 2024: $1,212 · 2025: $1,283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,006.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,006.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,341.60 | 2019-2025 | Ubrelvy, Qulipta, Vraylar |
| Pfizer INC. | $1,005.74 | 2019-2025 | |
| Amgen INC. | $795.81 | 2019-2025 | Repatha, Otezla, Evenity |
| Glaxosmithkline, LLC. | $777.17 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $646.77 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Novo Nordisk INC | $509.32 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $410.09 | 2019-2025 | Farxiga, Airsupra |
| Otsuka America Pharmaceutical, INC. | $331.10 | 2022-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $328.75 | 2019-2025 | Capvaxive, Gardasil, Gardasil 9 |
| Novartis Pharmaceuticals Corporation | $251.19 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $234.50 | 2019-2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $217.66 | 2019-2023 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $216.85 | 2019-2025 | Xifaxan, Trulance |
| Esperion Therapeutics, INC. | $206.17 | 2020-2025 | Nexletol |
| Allergan, INC. | $175.84 | 2019-2020 |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Cook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.